MedTrace Logo

Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes

NCT02637973 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2023-06-05

No results posted yet for this study

Summary

The effects of empagliflozin treatment on hepatocellular lipid content, liver energy metabolism and body composition will be investigated in a multicentre, prospective, placebo-controlled, double-blind, randomized, 2-arm parallel, interventional and exploratory pilot study in patients with newly diagnosed type 2 diabetes.

Conditions

Interventions

DRUG

Empagliflozin

25 mg once daily

DRUG

Placebo

once daily

Sponsors & Collaborators

  • Boehringer Ingelheim

    collaborator INDUSTRY

  • The Deutsche Diabetes Forschungsgesellschaft e.V.

    lead OTHER

Principal Investigators

  • Michael Roden, MD · Deutsches Diabetes Zentrum

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2018-08-31
Completion
2018-08-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02637973 on ClinicalTrials.gov